Molomics advances the search for structurally novel small molecule therapeutics by Artificial Intelligence (AI) through integrating it with a team (Experts). As molecules are designed collaboratively in silico between machine and humans, we expect that our drug candidates are more efficacious and safer, increasing the success rates in clinical development.
It is very challenging to determine highly effective and safe therapeutics. Molomics Technology overcomes this challenge by integrating your and other Experts of your choice with Artificial Intelligence (AI) to collaboratively design high potential drug candidates with diverse structures in real-time. The process generates quality drug information by machine learning methods and human knowledge to come up with optimal drug candidates.
(e.g. Machine Learning)
Consensus Decision Making
Molomics principal focus is Parkinson's Disease (PD). Current programs address Levodopa Induced Dyskinesia (LID). Strategies related to GPCRs (G Protein-Coupled Receptors) like allosteric modulation are applied in drug discovery and development.
Our drug discovery programs advance through three phases: the Feasibility Study, the Drug Design Phase and a partial Preclinical Analysis. We work with research institutes and industry partners like biotech and pharma to unlock new opportunities and to assure the design of efficacious and safer drugs.
Molomics wants to partner with selected biotechs or pharma companies in their disease area of interest. Molomics drug design approach, driven by its proprietary technology, is further re-inforced by state of the art project management: